|
Re: Seeking Alpha mention
|
2
|
Resverlogix Corp.
|
Aug 23, 2019 09:02AM
|
|
Re: Seeking Alpha Blog post...
|
6
|
Resverlogix Corp.
|
Feb 13, 2019 02:57PM
|
|
Re: Seeking Alpha articles
|
9
|
Resverlogix Corp.
|
Aug 05, 2017 03:47PM
|
|
Re: Sedar filings - Loan balance
|
2
|
Resverlogix Corp.
|
Jul 31, 2019 01:13PM
|
|
Re: Secondary indications
|
5
|
Resverlogix Corp.
|
Jan 24, 2019 12:43PM
|
|
Re: Secondary endpoints
|
5
|
Resverlogix Corp.
|
Oct 22, 2019 09:34PM
|
|
Re: Screening/NR Tmr morn Dosing has begun?
|
6
|
Resverlogix Corp.
|
Dec 19, 2021 05:18PM
|
|
Re: Science
|
7
|
Resverlogix Corp.
|
Oct 24, 2017 02:54PM
|
|
Re: Scenario Analysis on end of BETonMACE Phase 3
|
4
|
Resverlogix Corp.
|
Apr 15, 2019 04:09PM
|
|
Re: Saw these articles that might be relevant to us,...
|
6
|
Resverlogix Corp.
|
Sep 20, 2018 07:15PM
|
|
Re: Sarah's response...
|
2
|
Resverlogix Corp.
|
Apr 25, 2017 08:15PM
|
|
Re: Safety, tolerability and efficacy for CKD and Fabry trials!
|
4
|
Resverlogix Corp.
|
Jul 16, 2018 10:33AM
|
|
Re: Safety and Efficacy
|
2
|
Resverlogix Corp.
|
Mar 03, 2017 06:20PM
|
|
Re: Safety and Efficacy
|
7
|
Resverlogix Corp.
|
Mar 03, 2017 10:00AM
|
|
Re: SA blog post for those interested.....
|
6
|
Resverlogix Corp.
|
Apr 17, 2019 09:29AM
|
|
Re: RVXCF New 52 week high, $3.59 USD....
|
4
|
Resverlogix Corp.
|
Apr 23, 2019 10:34AM
|
|
Re: RVXCF New 52 week high, $3.59 USD....
|
3
|
Resverlogix Corp.
|
Apr 23, 2019 10:41AM
|
|
Re: RVX-297, a BET Bromodomain Inhibitor, Has Therapeutic Effects in Preclinical Models of Acute Inflammation and Autoimmune Disease
|
5
|
Resverlogix Corp.
|
Jan 24, 2018 09:41PM
|
|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
2
|
Resverlogix Corp.
|
Jan 08, 2019 09:12AM
|
|
Re: RVX-297 vs RVX-208 for autoimmune indications
|
3
|
Resverlogix Corp.
|
Jan 08, 2019 10:21AM
|
